ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. FICO
8. CART
9. LLY
10. TSLA

Go back to ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results

Immunogen (IMGN) Tops Q2 EPS by 4c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus

August 2, 2019 6:38 AM EDT

Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.29), $0.04 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $15.54 million versus the consensus estimate of $9.48 million.

Registration Study for Mirvetuximab Soravtansine in Ovarian Cancer on Track to Start by Year-EndFull Data from the Phase 3 FORWARD I Trial and Initial FORWARD II Triplet Data to be Presented at ESMORecommended Phase 2 Dose and Schedule for IMGN632 Determined; Combination and MRD+ Protocol... More